Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
03/2003
03/20/2003WO2002094768A3 Aza hydroxylated ethyl amine compounds
03/20/2003WO2002091993A3 Estrogen receptor modulators
03/20/2003WO2002088136A3 Antidepressant azaheterocyclylmethyl derivatives of 1,4,5-trioxa-phenanthrene
03/20/2003WO2002087424A3 Treatment and diagnosis of macrophage mediated disease
03/20/2003WO2002079404A3 Cytoskeleton-associated proteins
03/20/2003WO2002074758A3 Novel amines as histamine-3 receptor ligands and their therapeutic applications
03/20/2003WO2002067865A3 N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof
03/20/2003WO2002066040A8 Sensitization of chemotherapeutic agent resistant neoplastic cells with reovirus
03/20/2003WO2002058635A3 Nicotine immunogens and antibodies and uses thereof
03/20/2003WO2002050255A3 Isolated human dehydrogenases, nucleic acid molecules encoding them, and uses thereof
03/20/2003WO2002047688A3 Method and apparatus for treating breakthrough pain
03/20/2003WO2002046189A3 Aryl ether substituted imidazoquinolines
03/20/2003WO2002036166A8 Compositions for stimulating cd45 and thereby suppressing microglial activation associated with alzheimer's disease
03/20/2003WO2002032412A3 Combination use of acetylcholinesterase inhibitors and gabaa inverse agonists for the treatment of cognitive disorders
03/20/2003WO2002021138A3 The m30 gene family and the utilization thereof
03/20/2003WO2002020736A3 Proteases
03/20/2003WO2002018445A9 Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design
03/20/2003WO2002012245B1 Azabicyclic derivatives and their therapeutic use
03/20/2003WO2002004520A3 Transporters and ion channels
03/20/2003WO2002004490A3 Lipid metabolism molecules
03/20/2003WO2001087913A9 Method for treating retinal degeneration with purinergic receptor agonists
03/20/2003US20030055286 Il-8 receptor antagonists
03/20/2003US20030055260 Il-8 receptor antagonists
03/20/2003US20030055250 Pteridine compounds for the treatment of psoriasis
03/20/2003US20030055249 Synthesis and methods of use of pyrimidine analogues and derivatives
03/20/2003US20030055248 Il-8 receptor antagonists
03/20/2003US20030055236 Secreted protein HKABT24
03/20/2003US20030055112 Dissolving sertraline hydrochloride in a suitable solvent; removing the solvent; drying to form sertraline hydrochloride
03/20/2003US20030055109 Stability
03/20/2003US20030055098 Method of treatment
03/20/2003US20030055097 Indazolyl-substituted pyrroline compounds as kinase inhibitors
03/20/2003US20030055093 For therapy of cardiovascular diseases, stable or unstable angina pectoris, coronary heart disease, stable or unstable angina pectoris, coronary heart disease, Prinzmetal angina, acute coronary syndrome, heart failure, myocardial infarction
03/20/2003US20030055091 Combination therapy comprising glucose reabsorption inhibitors and retinoid-X receptor modulators
03/20/2003US20030055088 Aryl substituted pyridines and the use thereof
03/20/2003US20030055081 For therapy of migraine
03/20/2003US20030055078 Use of phanquinone for the treatment or prevention of memory impairment
03/20/2003US20030055074 For use in therapy of psychic and neurological disorders
03/20/2003US20030055068 Pyrazole compounds useful as protein kinase inhibitors
03/20/2003US20030055061 Therapy of disease or condition which is caused by a disorder of the serotonin system by administering 2,7-substituted octahydro-1H-pyrido(1,2-a)pyrazine derivatives, and their acid addition salts
03/20/2003US20030055060 Imidazo-triazine derivatives as ligands for GABA receptors
03/20/2003US20030055055 For inducing and maintaining anesthesia, sedation and muscle relaxation, as well as for combating febrile convulsions in children
03/20/2003US20030055054 CXCR3 antagonists
03/20/2003US20030055050 CRF receptor antagonists and methods relating thereto
03/20/2003US20030055048 Compositions and methods for treating or preventing convulsions or seizures
03/20/2003US20030055047 For prevention and/or suppression of preterm labor, suppression of labor at term prior to caesarean delivery, and for the treatment of dysmenorrhea; useful in enhancing fertility rates
03/20/2003US20030055046 Novel pyrido cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists
03/20/2003US20030055045 Novel compounds with analgesic effect
03/20/2003US20030055044 Administering pyrazole derivative for inhibiting GSK-3 or Aurora activity in a patient
03/20/2003US20030055043 Substituted azabicyclic moieties for the treatment of disease
03/20/2003US20030055042 Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
03/20/2003US20030055040 Cholinesterase inhibitors to treat disorders of attention
03/20/2003US20030055037 Benzimidazole and indole derivatives as CRF receptor modulators
03/20/2003US20030055035 Useful in hyperpolarizing cell membranes, opening potassium channels, relaxing smooth muscle cells, and inhibiting bladder contractions
03/20/2003US20030055033 Azetidine derivatives, their preparation and pharmaceutical compositions containing them
03/20/2003US20030055032 For therapy or inhibiting the development of a pathology associated with peroxynitrite damage
03/20/2003US20030055031 As anticonvulsants; for therapy and prophylaxis of ischaemias, anoxia, neurodegenerative diseases
03/20/2003US20030055023 Injectable formulation of a sedative hypnotic drug, such as the anesthetic drug etomidate, that is pharmaceutically stable, demonstrates a reduced incidence of pain upon injection
03/20/2003US20030055012 Prodrugs of COX-2 inhibitors
03/20/2003US20030055005 Gamma-secretase inhibitors
03/20/2003US20030055004 GPE analogs and peptidominetics
03/20/2003US20030055003 Administering copper chelator and activated protein C (APC) or protein C or agent that increases the synthesis of protein C in the animal, or both, an activator of protein C for therapy
03/20/2003US20030054998 Prolactin induced increase in neural stem cell numbers
03/20/2003US20030054990 Methods of using neural thread proteins to treat tumors and other conditions requiring the removal or destruction of cells
03/20/2003US20030054980 Ceruloplasmin and uses thereof in neurodegenerative related conditions
03/20/2003US20030054974 Non-oxidatively metabolized compounds and compositions, synthetic pathways therefor, and uses thereof
03/20/2003US20030054551 Amplification of neuronal stem cells; prepare nutrient broth, mix with modulator, inoculate with stem cells monitor propagation activity in cells
03/20/2003US20030054409 Novel complex-forming proteins
03/20/2003US20030054397 Methods and compositions for the detection and treatment of multiple sclerosis
03/20/2003US20030054345 Compositions and methods for the diagnosis and treatment of neuropsychiatric disorders, including schizophrenia
03/20/2003US20030054049 Stress relieving perfume and stress relieving perfume compositions containing the same
03/20/2003US20030054037 Pharmaceutical compositions of adsorbates of amorphous drug
03/20/2003US20030054034 Water soluble film forming polymer and microbiocide oil
03/20/2003US20030054015 Mixture of vegetable oil, aromatic solvent and caffeine; nerve stimulant perfume
03/20/2003US20030054014 Administering fungi spores; aging resistance
03/20/2003US20030053990 Virus vectors and methods of making and administering the same
03/20/2003CA2461692A1 Use of a protein of the crmp family for treating diseases related to the immune system
03/20/2003CA2460348A1 Methods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites
03/20/2003CA2460092A1 A method of diagnosis and treatment and agents useful for same
03/20/2003CA2460075A1 Substituted 7-aza[2.2.1] bicycloheptanes for the treatment of diseases
03/20/2003CA2459973A1 Carbazole derivatives and their use as npy5 receptor antagonists
03/20/2003CA2459890A1 Crystal structure of baff, and use thereof in drug design
03/20/2003CA2459760A1 Method for preparing unsaturated fatty hydroxy-acids and esters thereof, their use in pharmaceutical and/or cosmetic compositions
03/20/2003CA2459531A1 Heterocyclic substituted 2- (4-phenoxy) pyridine derivatives and related compounds as sodium channel blockers for the treatment of neuronal damage and neurodegenerative conditions
03/20/2003CA2459527A1 Aryl substituted pyridinecarboxamides and their use as sodium channel blockers
03/20/2003CA2459515A1 Indole derivatives
03/20/2003CA2459469A1 Pharmaceutical composition for diabetic neuropathy
03/20/2003CA2459464A1 Tetrahydropyran derivatives and their use as therapeutic agents
03/20/2003CA2459304A1 Combination of an adenosine a2a receptor antagonist and an antidepressant or anxiolytic
03/20/2003CA2458628A1 Use of substituted aminomethyl chromans in the treatment of movement disorders
03/20/2003CA2458029A1 Methods of treating cytokine mediated diseases
03/20/2003CA2451454A1 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
03/20/2003CA2451254A1 Novel proteins and nucleic acids encoding same
03/19/2003EP1293570A2 Application of aprataxin gene to diagnosis and treatment for early-onset spinocerebellar ataxia (EAOH)
03/19/2003EP1293554A1 Stress-relieving perfumes and stress-relieving perfume compositions containing the same
03/19/2003EP1293511A1 Canine liver cell growth factor
03/19/2003EP1293510A1 Novel polypeptide and its dna
03/19/2003EP1293503A1 Triazole derivatives
03/19/2003EP1293213A1 Preventives/remedies for postoperative stress
03/19/2003EP1293209A1 Oral pharmaceutical dosage forms with reduced potential for drug abuse
03/19/2003EP1293200A1 Nerve growth factor activity potentiating agents
1 ... 1236 1237 1238 1239 1240 1241 1242 1243 1244 1245 1246 1247 1248 1249 1250 1251 1252 1253 1254 1255 1256 ... 1833